AG-SILDENAFIL TABLETS

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SILDENAFIL (SILDENAFIL CITRATE)

可用日期:

ANGITA PHARMA INC.

ATC代码:

G04BE03

INN（国际名称）:

SILDENAFIL

剂量:

25MG

药物剂型:

TABLET

组成:

SILDENAFIL (SILDENAFIL CITRATE) 25MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0136261001; AHFS:

授权状态:

APPROVED

授权日期:

2020-08-14

产品特点

PRODUCT MONOGRAPH
PR
AG-SILDENAFIL TABLETS
Sildenafil (as Sildenafil citrate)
Tablets 25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
August
12, 2020
Date of
Revision
:
Submission
Control
No.:
239723
J4B 5H3
Boucherville,
Québec
1310 rue Nobel
Angita Pharma
Inc.
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................
4
ADVERSE REACTIONS
........................................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................................
12
DOSAGE AND ADMINISTRATION
...................................................................................................
15
OVERDOSAGE
.....................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.................................................................................
17
STORAGE AND STABILITY
..............................................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
............................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................. 20
PART II: SCIE